Novavax is yet to secure emergency use authorisation
Earlier this year, Novavax said its vaccine showed 93% efficacy against the Coronavirus. The strong Phase III results had the U.S. government’s operation Warp Speed pour in over a billion dollars to help Novavax ramp up production of its COVID vaccine.
Ever since, however, the U.S. firm has faced multiple manufacturing delays – more alarmingly in terms of making a “pure enough” vaccine that satisfies the quality standards laid out by the U.S. FDA.
Novavax is yet to win emergency use authorisation for its “protein vaccine” due to manufacturing delays. It recently partnered with a Polish biotech firm Mabion SA to produce its candidate Coronavirus vaccine. The four-year deal starts in December 2021.
Impact on the global battle against the pandemic
According to CNBC’s Meg Tirrell, the manufacturing issues are concerning as Novavax’s COVID vaccine is an important piece in the global battle against the pandemic.
They’ve made a lot of promises to the global vaccine effort, and if they can’t get this vaccine manufactured in a pure enough way and in large enough doses, then that’s going to deal a real blow to the global vaccination effort.
The sharp decline in share price today reflected shareholders were deeply disappointed in yet another manufacturing delay. The stock is now down more than 60% from its year-to-date high in early February.
The post Novavax shares opened 25% down on Wednesday: what happened? appeared first on Invezz.